Table 1.
Baseline characteristics of subjects by estrogen supplementation status.
| Women taking estrogen N = 12 |
Women not taking estrogen N = 37 |
p-value | |
|---|---|---|---|
| Age at clinic visit (years) | 31.4 (8.1) | 30.4 (7.1) | 0.69 |
| F508del homozygous (%) | 33.3% | 56.8% | 0.16 |
| At least one copy of F508del (%) | 83.3% | 89.2% | 0.63 |
| Caucasian (%) | 75.0% | 89.2% | 0.34 |
| Not caucasian (%) | 25.0% | 10.8% | |
| CF-related diabetes (%) | 25.0% | 37.8% | 0.50 |
| No CF-related diabetes (%) | 75.0% | 62.2% | |
| Hemoglobin A1C (%) | 6.1 (1.4) | 5.7 (0.8) | 0.89 |
| Exocrine pancreatic insufficiency (%) | 83.3% | 97.3% | 0.14 |
| No exocrine pancreatic insufficiency (%) | 16.7% | 2.7% | |
| Vitamin D (25-hydroxyvitamin D) (ng/mL) | 31.9 (17.6) | 27.1 (11.2) | 0.41 |
| Using anti-osteoporosis medication (anti-resorptive or anabolic agents) | 0.0% | 0.0% | |
| Systemic glucocorticoid use (%) | 8.3% | 3.7% | 0.43 |
| Not on systemic glucocorticoid (%) | 91.7% | 97.3% | |
| History of lung or liver transplant (%) | 8.3% | 0.0% | 0.24 |
| Number of hospitalizations in previous year | 0.8 (1.1) | 1.4 (1.8) | 0.27 |
| Height (cm) | 160.1 (5.4) | 160.2 (5.3) | 0.99 |
| Weight (kg) | 56.2 (12.3) | 58.4 (14.4) | 0.63 |
| BMI (kg/m2) | 21.9 (4.5) | 22.8 (5.7) | 0.64 |
| FEV1 % predicted (%) | 61.9 (28.3) | 62.6 (25.0) | 0.95 |
| FVC % predicted (%) | 76.1 (22.7) | 81.3 (22.1) | 0.51 |
| CFTR modulator use (%) | 33.3% | 48.6% | 0.35 |
| No CFTR modulator use (%) | 66.7% | 51.4% |
Mean (SD) reported for continuous variables, and percentage reported for categorical variables.